Selective serotonin uptake inhibitor: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
In [[medicine]], '''serotonin uptake inhibitors''' are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft.
{{subpages}}
In [[medicine]], '''selective serotonin uptake inhibitors''' (SSRI) are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft. These were the initial subgroup of the second generation, demonstrating generally improved side effects over the first-generation [[tricyclic antidepressant]]s and [[monoamine oxidase inhibitor]]s.
 
While SSRIs remain the group most often prescribed, both clinical response and side effects vary with individual patients.  An atypical second-generation drug such as [[venlafaxine]] may induce faster and more reliable relief of depression, but also may have more side effects.<ref>{{citation
| journal = Br. J. Psychiatry
| year = 2001
| url = http://www.hawaii.edu/hivandaids/Remission%20Rates%20During%20Treatment%20With%20Venlafaxine%20Or%20Selective%20Serotonin%20Reuptake%20Inhibitors.pdf
| author = Thase ME; Entsuah R; Rudolph RL
| title = Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
}}</ref>


==Examples==
==Examples==
* [[Citalopram]] (generic). Can be combined with [[bupropion]].
* [[Citalopram]] (generic). Can be combined with [[bupropion]].
* [[Duloxetine]]. Inhibits [[cytochrome P-450 CYP2D6]].
* [[Duloxetine]]. A  moderate inhibitor of[[cytochrome P-450 CYP2D6]].<ref name="IndianaP450">[http://medicine.iupui.edu/clinpharm/ddis/table.asp P450 Drug Interaction Table]</ref>
* [[Fluoxetine]] (generic). Inhibits [[cytochrome P-450 CYP2D6]].
* [[Fluoxetine]] (generic). A strong inhibitor of [[cytochrome P-450 CYP2D6]].<ref name="IndianaP450">[http://medicine.iupui.edu/clinpharm/ddis/table.asp P450 Drug Interaction Table]</ref>
* [[Paroxetine]] (generic). Inhibits [[cytochrome P-450 CYP2D6]]. May increase death from [[breast cancer]] among women taking [[tamoxifen]] due to inhibiting metabolism of [[tamoxifen]] to itc active metabolite by [[cytochrome P-450 CYP2D6]].<ref>{{Cite journal
* [[Paroxetine]] (generic). A strong inhibitor of [[cytochrome P-450 CYP2D6]].<ref name="IndianaP450">[http://medicine.iupui.edu/clinpharm/ddis/table.asp P450 Drug Interaction Table]</ref> May increase death from [[breast cancer]] among women taking [[tamoxifen]] due to inhibiting metabolism of [[tamoxifen]] to itc active metabolite by [[cytochrome P-450 CYP2D6]].<ref>{{Cite journal
| doi = 10.1136/bmj.c693 | volume = 340 | issue = feb08_1 | pages = c693 | last = Kelly | first = Catherine M | coauthors = David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
| doi = 10.1136/bmj.c693 | volume = 340 | issue = feb08_1 | pages = c693 | last = Kelly | first = Catherine M | coauthors = David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
| journal = BMJ | accessdate = 2010-02-10 | date = 2010-02-08 | url = http://www.bmj.com/cgi/content/abstract/340/feb08_1/c693 }}</ref>
| journal = BMJ | accessdate = 2010-02-10 | date = 2010-02-08 | url = http://www.bmj.com/cgi/content/abstract/340/feb08_1/c693 }}</ref>
* [[Sertraline]] (generic)
* [[Sertraline]] (generic) Inexpensive, moderate inhibitor of [[cytochrome P-450 CYP2D6]].<ref name="IndianaP450">[http://medicine.iupui.edu/clinpharm/ddis/table.asp P450 Drug Interaction Table]</ref>


==References==
==References==
<references/>
<references/>

Latest revision as of 08:46, 13 February 2011

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In medicine, selective serotonin uptake inhibitors (SSRI) are second-generation antidepressants that potentiate the effect of serotonin by blocking its uptake from the synaptic cleft. These were the initial subgroup of the second generation, demonstrating generally improved side effects over the first-generation tricyclic antidepressants and monoamine oxidase inhibitors.

While SSRIs remain the group most often prescribed, both clinical response and side effects vary with individual patients. An atypical second-generation drug such as venlafaxine may induce faster and more reliable relief of depression, but also may have more side effects.[1]

Examples

References

  1. Thase ME; Entsuah R; Rudolph RL (2001), "Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors", Br. J. Psychiatry
  2. 2.0 2.1 2.2 2.3 P450 Drug Interaction Table
  3. Kelly, Catherine M; David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat (2010-02-08). "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340 (feb08_1): c693. DOI:10.1136/bmj.c693. Retrieved on 2010-02-10. Research Blogging.